{"id":56918,"date":"2026-02-11T23:09:29","date_gmt":"2026-02-11T15:09:29","guid":{"rendered":"https:\/\/flcube.com\/?p=56918"},"modified":"2026-02-11T23:09:30","modified_gmt":"2026-02-11T15:09:30","slug":"newsoara-biopharma-expands-global-rights-to-vtvs-pde4-inhibitor-hpp737-in-135-million-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56918","title":{"rendered":"Newsoara BioPharma Expands Global Rights to vTv\u2019s PDE4 Inhibitor HPP737 in $135 Million Deal"},"content":{"rendered":"\n

Newsoara BioPharma Co., Ltd.<\/strong> and vTv Therapeutics LLC<\/strong> have expanded their strategic collaboration<\/strong>, with Newsoara securing global rights<\/strong> to HPP737<\/strong>, a novel phosphodiesterase-4 (PDE4) inhibitor<\/strong> in development for psoriasis<\/strong>. The expanded agreement, valued at up to USD\u202f135 million<\/strong> including a USD\u202f20 million upfront payment<\/strong>, builds on their 2018 Asia-Pacific partnership<\/strong> and positions Newsoara to commercialize the anti-inflammatory therapy worldwide<\/strong>.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>vTv Therapeutics LLC (US-based)<\/td><\/tr>
Licensee<\/strong><\/td>Newsoara BioPharma Co., Ltd. (China)<\/td><\/tr>
Asset<\/strong><\/td>HPP737 \u2013 Selective PDE4 inhibitor<\/td><\/tr>
Prior Rights<\/strong><\/td>China and Asia-Pacific (2018 agreement)<\/td><\/tr>
Expanded Rights<\/strong><\/td>Global<\/strong> (ex-Asia-Pacific now included)<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD\u202f20 million<\/strong><\/td><\/tr>
Total Consideration<\/strong><\/td>Up to USD\u202f135 million<\/strong> (milestones and royalties)<\/td><\/tr>
Target Indication<\/strong><\/td>Psoriasis (with potential expansion to other inflammatory diseases)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism of Action<\/h2>\n\n\n\n
Feature<\/th>HPP737 Specification<\/th>Differentiation<\/th><\/tr><\/thead>
Target<\/strong><\/td>Phosphodiesterase-4 (PDE4)<\/strong><\/td>Well-validated anti-inflammatory target (apremilast precedent)<\/td><\/tr>
Selectivity<\/strong><\/td>Potent and selective PDE4 inhibition<\/strong><\/td>Reduced off-target effects vs. non-selective PDE inhibitors<\/td><\/tr>
Anti-Inflammatory Mechanism<\/strong><\/td>IL-23 and TNF-\u03b1 suppression<\/strong> (in vitro and in vivo)<\/td>Dual cytokine inhibition; potential for superior efficacy<\/td><\/tr>
Preclinical Validation<\/strong><\/td>Therapeutic activity in multiple animal inflammation models<\/strong><\/td>Strong translational rationale for human psoriasis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Evolution & Market Context<\/h2>\n\n\n\n
Timeline<\/th>Milestone<\/th>Strategic Significance<\/th><\/tr><\/thead>
2018<\/strong><\/td>Newsoara secures China\/Asia-Pacific rights<\/strong><\/td>Initial partnership; regional development focus<\/td><\/tr>
2026<\/strong><\/td>Global rights expansion<\/strong><\/td>Newsoara positions as worldwide commercialization partner<\/strong>; vTv monetizes asset with limited ex-US infrastructure<\/td><\/tr>
Development Stage<\/strong><\/td>Preclinical\/early clinical (psoriasis)<\/td>Phase I\/II initiation<\/strong> anticipated; competitive PDE4 landscape requires differentiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n